Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-1524. [Abstract]
Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-135. [Medline]
Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003;88:3474-3481. [Free Full Text]
Cooper DS. Antithyroid drugs. N Engl J Med 1984;311:1353-1362. [Abstract]
Marchant B, Alexander WD, Robertson JWK, Lazarus JH. Concentration of 35S-propylthiouracil by the thyroid gland and its relationship to anion trapping mechanism. Metabolism 1971;20:989-999. [CrossRef][ISI][Medline]
Davidson B, Soodak M, Neary JT, et al. The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings. Endocrinology 1978;103:871-882. [Abstract]
Taurog A. Hormone synthesis and secretion. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid: a fundamental and clinical text. Philadelphia: Lippincott-Raven, 1996:47-80.
McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 1980;303:302-307. [Abstract]
Sonnet E, Massart C, Gibassier J, Allannic H, Maugendre D. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest 1999;22:430-435. [ISI][Medline]
Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995;25:654-658. [Erratum, Eur J Clin Invest 1996:26:341.] [ISI][Medline]
Salvi M, Girasole G, Pedrazzoni M, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996;81:2976-2979. [Abstract]
Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP, Koutras DA. Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Thyroid 2000;10:527-532. [ISI][Medline]
Zantut-Wittmann DE, Tambascia MA, da Silva Trevisan MA, Pinto GA, Vassallo J. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease. Thyroid 2001;11:575-580. [CrossRef][ISI][Medline]
Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 1987;316:15-22. [Abstract]
Wang PW, Luo SF, Huang BY, Lin JD, Huang MJ. Depressed natural killer activity in Graves' disease and during antithyroid medication. Clin Endocrinol (Oxf) 1988;28:205-214. [ISI][Medline]
Corrales JJ, Lopez A, Ciudad J, Mories MT, Miralles JM, Orfao A. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells. J Endocrinol 1997;155:491-500. [Abstract]
Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 2001;7:451-460. [CrossRef][ISI][Medline]
Davies TF, Weiss I, Gerber MA. Influence of methimazole on murine thyroiditis: evidence for immunosuppression in vivo. J Clin Invest 1984;73:397-404. [ISI][Medline]
Reinhardt W, Appel MC, Alex S, Yang YN, Braverman LE. The inhibitory effect of large doses of methimazole on iodine induced lymphocytic thyroiditis and serum anti-thyroglobulin antibody titers in BB/Wor rats. J Endocrinol Invest 1989;12:559-563. [ISI][Medline]
Wilson R, McKillop JH, Pearson C, Burnett AK, Thomson JA. Differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol 1988;73:312-315. [ISI][Medline]
Cooper DS, Saxe VC, Meskell M, Maloof F, Ridgway EC. Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab 1982;54:101-107. [ISI][Medline]
Cooper DS, Bode HH, Nath B, Saxe V, Maloof F, Ridgway EC. Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab 1984;58:473-479. [Abstract]
Barnes HV, Bledsoe T. A simple test for selecting the thioamide schedule in thyrotoxicosis. J Clin Endocrinol Metab 1972;35:250-255. [ISI][Medline]
Jansson R, Dahlberg PA, Johansson H, Lindstrom B. Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab 1983;57:129-132. [Abstract]
McCruden DC, Hilditch TE, Connell JMC, McLellan AR, Robertson J, Alexander WD. Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test. Clin Endocrinol (Oxf) 1987;26:33-39. [ISI][Medline]
Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H. Treatment of hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol (Copenh) 1988;119:139-144. [Medline]
Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995;88:973-976. [ISI][Medline]
Hoffman WH, Miceli JN. Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. Dev Pharmacol Ther 1988;11:73-81. [ISI][Medline]
Kampmann JP, Mortensen HB, Bach B, Waldorff S, Kristensen MB, Hansen JM. Kinetics of propylthiouracil in the elderly. Acta Med Scand Suppl 1979;624:93-98. [Medline]
Jansson R, Lindstrom B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 1985;10:443-450. [ISI][Medline]
Cooper DS, Steigerwalt S, Migdal S. Pharmacology of propylthiouracil in thyrotoxicosis and chronic renal failure. Arch Intern Med 1987;147:785-786. [Abstract]
Giles HG, Roberts EA, Orrego H, Sellers EM. Determination of free propylthiouracil clearance and single sample prediction of steady state. J Pharm Pharmacol 1982;34:62-64. [ISI][Medline]
Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-1738. [Abstract]
Torring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine -- a prospective, randomized study. J Clin Endocrinol Metab 1996;81:2986-2993. [Abstract]
Ljunggren JG, Torring O, Wallin G, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998;8:653-659. [ISI][Medline]
Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective randomized study. J Clin Endocrinol Metab 2001;86:3488-3493. [Free Full Text]
Nakazato N, Yoshida K, Mori K, et al. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease. Thyroid 1999;9:775-779. [ISI][Medline]
Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism: Standards of Care Committee, American Thyroid Association. JAMA 1995;273:808-812. [Abstract]
Kallner G, Vitols S, Ljunggren JG. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. J Intern Med 1996;239:525-529. [CrossRef][ISI][Medline]
Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 2001;54:385-390. [CrossRef][ISI][Medline]
He CT, Hsieh AT, Pei D, et al. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 2004;60:676-681. [CrossRef][ISI][Medline]
DestinationRx home page. (Accessed January 13, 2005, at http://www.destinationrx.com.)
Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. J Clin Endocrinol Metab 1993;76:1516-1521. [Abstract]
Page SR, Sheard CE, Herbert M, Hopton M, Jeffcoate WJ. A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf) 1996;45:511-516. [Erratum, Clin Endocrinol (Oxf) 1997;46:240.] [CrossRef][ISI][Medline]
Hegedüs L, Hansen JM, Bech K, et al. Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment. Acta Endocrinol (Copenh) 1984;107:482-488. [Medline]
Schleusener H, Schwander J, Fischer C, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989;120:689-701. [Erratum, Acta Endocrinol (Copenh) 1989;121:304.] [Medline]
Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369-375. [ISI][Medline]
Benker G, Rienwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. Clin Endocrinol (Oxf) 1998;49:451-457. [CrossRef][ISI][Medline]
Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998;8:119-124. [ISI][Medline]
Fukao A, Takamatsu J, Murakami Y, et al. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease. Clin Endocrinol (Oxf) 2003;58:550-555. [CrossRef][ISI][Medline]
Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long-term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994;78:98-102. [Abstract]
Schott M, Morgenthaler NG, Fritzen R, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 2004;36:92-96. [CrossRef][ISI][Medline]
Nedrebo BG, Holm PI, Uhlving S, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 2002;147:583-589. [Abstract]
Teng CS, Yeung RTT. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 1980;50:144-147. [Abstract]
Werner RS, Romaldini JH, Farah CS, Werner MC, Bromberg N. Serum thyroid stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease. Thyroid 1991;1:293-299. [Medline]
Jorde R, Ytre-Arne K, Stormer J, Sunds-fjord J. Short-term treatment of Graves' disease with methimazole in high versus low doses. J Intern Med 1995;238:161-165. [ISI][Medline]
Wilson R, Buchanan L, Fraser WD, McKippop JH, Thomsen JA. Do higher doses of carbimazole improve remission in Graves' disease? QJM 1996;89:381-385. [Abstract]
Grebe SKG, Feek CM, Ford HC, et al. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol (Oxf) 1998;48:585-592. [CrossRef][ISI][Medline]
Paschke R, Vogg M, Kristoferitsch R, et al. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. J Clin Endocrinol Metab 1995;80:2470-2474. [Abstract]
Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990;70:675-679. [Abstract]
Garcia-Mayor RVG, Paramo C, LunaCano R, Perez Mendez LF, Galofre JC, Andrade A. Antithyroid drug and Graves' hyperthyroidism: significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 1992;15:815-820. [ISI][Medline]
Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves' disease -- prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999;50:127-132. [CrossRef][ISI][Medline]
Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2004;2:CD003420-CD003420. [Medline]
Slingerland DW, Burrows BA. Long-term antithyroid treatment in hyperthyroidism. JAMA 1979;242:2408-2410. [Abstract]
Hashizume K, Ichikawa I, Sakurai A, et al. Administration of thyroxine in treated Graves' disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324:947-953. [Abstract]
McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996;334:220-224. [Free Full Text]
Rittmaster RS, Zwicker H, Abbott EC, et al. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. J Clin Endocrinol Metab 1996;81:3283-3288. [Abstract]
Pfeilschifter J, Zeigler R. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume. Eur J Endocrinol 1997;136:81-86. [Abstract]
Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clin Endocrinol (Oxf) 1992;36:585-590. [ISI][Medline]
Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Clin Endocrinol (Oxf) 1989;31:209-218. [ISI][Medline]
Berglund J, Christensen SB, Dymling JF, Hallengren B. The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmö during the period 1970-1974. J Intern Med 1991;229:435-442. [ISI][Medline]
Amino N, Tanizawa O, Mori H, et al. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease. J Clin Endocrinol Metab 1982;55:108-112. [Abstract]
Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents. J Clin Invest 1979;64:1429-1436. [ISI][Medline]
Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid 2002;12:135-139. [CrossRef][ISI][Medline]
Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004;14:525-530. [CrossRef][ISI][Medline]
Bonnema SJ, Bennedbæk FN, Veje A, Marving J, Hegedus L. Propylthiouracil before 131I therapy of hyperthyroid disease: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004;89:4439-4444. [Free Full Text]
Cooper DS. The side effects of antithyroid drugs. Endocrinologist 1999;9:457-476. [ISI]
Ducornet B, Duprey J. Effects secondaires des antithyroidiens de synthese. Ann Med Interne (Paris) 1988;139:410-431. [ISI][Medline]
Meyer-Gessner M, Benker G, Olbricht T, et al. Nebenwirkungen der antithyreoidalen Therapie der hyperthyreose. Dtsch Med Wochenschr 1989;114:166-171. [ISI][Medline]
Shabtai R, Shapiro MS, Orenstein D, Taragan R, Shenkman L. The antithyroid arthritis syndrome reviewed. Arthritis Rheum 1984;27:227-229. [ISI][Medline]
Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 2004;14:459-462. [CrossRef][ISI][Medline]
Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) 2004;61:589-594. [CrossRef][ISI][Medline]
Toth EL, Mant MJ, Shivji S, Ginsberg J. Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am J Med 1988;85:725-727. [CrossRef][ISI][Medline]
Berkman EM, Orlin JB, Wolfsdorf J. An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome. Transfusion 1983;23:135-138. [CrossRef][ISI][Medline]
Fibbe WE, Claas FHJ, Van der Star-Dijkstra W, Schaafsma MR, Meyboom RH, Falkenburg JH. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol 1986;64:363-373. [ISI][Medline]
Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol 2002;127:92-98. [CrossRef][ISI][Medline]
Tajiri J, Noguchi S, Murakami N. Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Thyroid 1997;7:575-578. [ISI][Medline]
Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am 1998;27:225-247. [CrossRef][ISI][Medline]
Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism: the Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. BMJ 1996;313:539-544. [Free Full Text]
Sheng WH, Hung CC, Chen YC, et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. QJM 1999;92:455-461. [Free Full Text]
Andres E, Kurtz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F. Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis. QJM 2001;94:423-428. [Free Full Text]
Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991;79:366-371. [ISI][Medline]
Tajiri J, Noguchi S, Okamura S, et al. Granulocyte colony-stimulating factor treatment of antithyroid drug-induced granulocytopenia. Arch Intern Med 1993;153:509-514. [Abstract]
Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999;9:29-31. [ISI][Medline]
Liaw Y-F, Huang M-J, Fan K-D, Li K-L, Wu S-S, Chen T-J. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. Ann Intern Med 1993;118:424-428. [Free Full Text]
Gurlek A, Cobaukara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy. J Clin Gastroenterol 1997;24:180-183. [CrossRef][ISI][Medline]
Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-1733. [Free Full Text]
Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003;37:224-228. [Free Full Text]
Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023. [CrossRef][ISI][Medline]
Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995;80:1083-1085. [CrossRef][ISI][Medline]
Parker WA. Propylthiouracil-induced hepatotoxicity. Clin Pharm 1982;1:471-474. [Medline]
Horton RC, Sheppard MC, Emery P. Propylthiouracil-induced systemic lupus erythematosus. Lancet 1989;2:568-568. [Medline]
Gunton JE, Stiel J, Caterson RJ, McElduff A. Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis: a case report and review of the literature. J Clin Endocrinol Metab 1999;84:13-16. [Free Full Text]
Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10:595-599. [ISI][Medline]
Case Records of the Massachusetts General Hospital (Case 21-2002.) N Engl J Med 2002;347:122-30.
Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: implications for agranulocytosis. Drug Metab Dispos 1991;19:354-359. [Abstract]
Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270-4273. [Free Full Text]
Guma M, Salinas I, Reverter JL, et al. Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole. J Clin Endocrinol Metab 2003;88:2141-2146. [Free Full Text]
Harper L, Chin L, Daykin J, et al. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004;60:671-675. [CrossRef][ISI][Medline]
Ikeda S, Schweiss JF. Excessive blood loss during operation in the patient treated with propylthiouracil. Can Anaesth Soc J 1982;29:477-480. [ISI][Medline]
Uchigata Y, Eguchi Y, Takayama-Hasumi S, Omori Y. Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan. Diabetes Res Clin Pract 1994;22:89-94. [CrossRef][ISI][Medline]
Taguchi M, Yokota M, Koyano H, Endo Y, Ozawa Y. Acute pancreatitis and parotitis induced by methimazole in a patient with Graves' disease. Clin Endocrinol (Oxf) 1999;51:667-670. [CrossRef][ISI][Medline]
Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001;86:2354-2359. [Free Full Text]
Gardner DF, Cruikshank DP, Hays PM, Cooper DS. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests. J Clin Endocrinol Metab 1986;62:217-220. [Abstract]
Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997;82:3099-3102. [Free Full Text]
Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 1997;82:3633-3636. [Free Full Text]
Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison of propylthiouracil and methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 1994;170:90-95. [ISI][Medline]
Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 1994;4:129-133. [ISI][Medline]
Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology 2001;64:262-266. [CrossRef][ISI][Medline]
Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf) 1984;20:695-700. [ISI][Medline]
Cheron RG, Kaplan MM, Larsen PR, Selenkow HA, Crigler JF Jr. Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease. N Engl J Med 1981;304:525-528. [ISI][Medline]
Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K. Antithyroid drug therapy for Graves' disease during pregnancy: optimal regimen for fetal thyroid status. N Engl J Med 1986;315:24-28. [Abstract]
Messer PM, Hauffa BP, Olbricht T, Benker G, Kotulla P, Reinwein D. Antithyroid drug treatment of Graves' disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta Endocrinol (Copenh) 1990;123:311-316. [Medline]
Eisenstein Z, Weiss M, Katz Y, Bank H. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J Pediatr 1992;151:558-559. [CrossRef][ISI][Medline]
Hamburger JL. Diagnosis and management of Graves' disease in pregnancy. Thyroid 1992;2:219-224. [ISI][Medline]
Momotani N, Yamashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf) 2000;53:177-181. [CrossRef][ISI][Medline]
Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J Endocrinol Invest 2002;25:493-496. [ISI][Medline]
Azizi F, Bahrainian M, Khamseh ME, Khoshniat M. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J Pediatr Endocrinol Metab 2003;16:1239-1243. [ISI][Medline]
American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-789. [Free Full Text]
Jongjaroenprasert W, Akarawut W, Chantasart D, Chailurkit L, Rajatanavin R. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid 2002;12:627-631. [CrossRef][ISI][Medline]
Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982;54:180-181. [Abstract]
Junik R, Sowinski J, Zamyslowska H, Gembicki M. Effect of intravenous methimazole on serum levels of thyroid hormones in patients with hyperthyroidism resistant to oral thyrostatic drugs. Endokrynol Pol 1989;40:307-313. [Medline]